Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Feb;102(2):518–522. doi: 10.1111/j.1476-5381.1991.tb12203.x

Pharmacological profile of various kappa-agonists at kappa-, mu- and delta-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain.

A H Mulder 1, D M Burger 1, G Wardeh 1, F Hogenboom 1, A L Frankhuyzen 1
PMCID: PMC1918010  PMID: 1673074

Abstract

1. The potency, relative efficacy and selectivity of a series of kappa-opioid receptor agonists at the mu-, delta- and kappa-opioid receptors mediating inhibition of electrically-induced (radiolabelled) neurotransmitter release from superfused rat brain slices was determined. 2. With regard to their potencies at kappa-receptors mediating inhibition of striatal [3H]-dopamine release, the highest pD2 value (8.7) was found for bremazocine and the lowest (7.1) for U50488; the pD2 values for ethylketocyclazocine (EKC), tifluadom, U69593 and PD117302 were between 8.0 and 8.3. There were no marked differences between the relative efficacies of the kappa-agonists (maximum inhibition being 60-70%). In contrast to the other kappa-agonists, at a concentration of 1 microM, PD117302 caused a significant (25-40%) increase of the spontaneous efflux of tritium. 3. None of the kappa-agonists significantly affected striatal [14C]-acetylcholine (ACh) release, with the exception of a slight inhibitory effect of EKC. The delta-receptor-mediated inhibitory effect of [D-Ala2, D-Leu5]enkephalin (DADLE) on [14C]-ACh release was antagonized in a concentration-dependent manner by bremazocine (0.1 and 1.0 microM) and also partially by EKC (1 microM), but not by the other kappa-agonists. The pA2 value for bremazocine as an antagonist at the delta-receptors involved was 8.0, compared to 7.6 for naloxone. 4. None of the kappa-agonists significantly affected cortical [3H]-noradrenaline (NA) release, with the notable exception of tifluadom, which strongly inhibited release by activating mu-receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
518

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clark C. R., Birchmore B., Sharif N. A., Hunter J. C., Hill R. G., Hughes J. PD117302: a selective agonist for the kappa-opioid receptor. Br J Pharmacol. 1988 Mar;93(3):618–626. doi: 10.1111/j.1476-5381.1988.tb10319.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clark M. J., Carter B. D., Medzihradsky F. Selectivity of ligand binding to opioid receptors in brain membranes from the rat, monkey and guinea pig. Eur J Pharmacol. 1988 Apr 13;148(3):343–351. doi: 10.1016/0014-2999(88)90112-4. [DOI] [PubMed] [Google Scholar]
  3. Corbett A. D., Kosterlitz H. W. Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus. Br J Pharmacol. 1986 Sep;89(1):245–249. doi: 10.1111/j.1476-5381.1986.tb11141.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dunwiddie T. V., Johnson K. J., Proctor W. R. Bremazocine differentially antagonizes responses to selective mu and delta opioid receptor agonists in rat hippocampus. Br J Pharmacol. 1987 Jul;91(3):523–530. doi: 10.1111/j.1476-5381.1987.tb11245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Frankhuyzen A. L., Mulder A. H. A cumulative dose-response technique for the characterization of presynaptic receptors modulating [3H]noradrenaline release from rat brain slices. Eur J Pharmacol. 1982 Feb 19;78(1):91–97. doi: 10.1016/0014-2999(82)90375-2. [DOI] [PubMed] [Google Scholar]
  6. Gillan M. G., Kosterlitz H. W., Magnan J. Unexpected antagonism in the rat vas deferens by benzomorphans which are agonists in other pharmacological tests. Br J Pharmacol. 1981 Jan;72(1):13–15. doi: 10.1111/j.1476-5381.1981.tb09098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gillan M. G., Kosterlitz H. W. Spectrum of the mu, delta- and kappa-binding sites in homogenates of rat brain. Br J Pharmacol. 1982 Nov;77(3):461–469. doi: 10.1111/j.1476-5381.1982.tb09319.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hayes A., Kelly A. Profile of activity of kappa receptor agonists in the rabbit vas deferens. Eur J Pharmacol. 1985 Apr 16;110(3):317–322. doi: 10.1016/0014-2999(85)90558-8. [DOI] [PubMed] [Google Scholar]
  9. Jackisch R., Geppert M., Illes P. Characterization of opioid receptors modulating noradrenaline release in the hippocampus of the rabbit. J Neurochem. 1986 Jun;46(6):1802–1810. doi: 10.1111/j.1471-4159.1986.tb08499.x. [DOI] [PubMed] [Google Scholar]
  10. Lahti R. A., Mickelson M. M., McCall J. M., Von Voigtlander P. F. [3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol. 1985 Feb 26;109(2):281–284. doi: 10.1016/0014-2999(85)90431-5. [DOI] [PubMed] [Google Scholar]
  11. Leighton G. E., Johnson M. A., Meecham K. G., Hill R. G., Hughes J. Pharmacological profile of PD 117302, a selective kappa-opioid agonist. Br J Pharmacol. 1987 Dec;92(4):915–922. doi: 10.1111/j.1476-5381.1987.tb11398.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Martin W. R. Pharmacology of opioids. Pharmacol Rev. 1983 Dec;35(4):283–323. [PubMed] [Google Scholar]
  13. McKnight A. T., Corbett A. D., Marcoli M., Kosterlitz H. W. The opioid receptors in the hamster vas deferens are of the delta-type. Neuropharmacology. 1985 Nov;24(11):1011–1017. doi: 10.1016/0028-3908(85)90184-4. [DOI] [PubMed] [Google Scholar]
  14. Miller L., Shaw J. S., Whiting E. M. The contribution of intrinsic activity to the action of opioids in vitro. Br J Pharmacol. 1986 Mar;87(3):595–601. doi: 10.1111/j.1476-5381.1986.tb10202.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mulder A. H., Hogenboom F., Wardeh G., Schoffelmeer A. N. Morphine and enkephalins potently inhibit [3H]noradrenaline release from rat brain cortex synaptosomes: further evidence for a presynaptic localization of mu-opioid receptors. J Neurochem. 1987 Apr;48(4):1043–1047. doi: 10.1111/j.1471-4159.1987.tb05624.x. [DOI] [PubMed] [Google Scholar]
  16. Mulder A. H., Wardeh G., Hogenboom F., Frankhuyzen A. L. Kappa- and delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature. 1984 Mar 15;308(5956):278–280. doi: 10.1038/308278a0. [DOI] [PubMed] [Google Scholar]
  17. Mulder A. H., Wardeh G., Hogenboom F., Frankhuyzen A. L. Selectivity of various opioid peptides towards delta-, kappa; and mu-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain. Neuropeptides. 1989 Aug-Sep;14(2):99–104. doi: 10.1016/0143-4179(89)90065-6. [DOI] [PubMed] [Google Scholar]
  18. Paterson S. J., Robson L. E., Kosterlitz H. W. Classification of opioid receptors. Br Med Bull. 1983 Jan;39(1):31–36. doi: 10.1093/oxfordjournals.bmb.a071787. [DOI] [PubMed] [Google Scholar]
  19. Römer D., Büscher H. H., Hill R. C., Maurer R., Petcher T. J., Zeugner H., Benson W., Finner E., Milkowski W., Thies P. W. An opioid benzodiazepine. Nature. 1982 Aug 19;298(5876):759–760. doi: 10.1038/298759a0. [DOI] [PubMed] [Google Scholar]
  20. Römer D., Büscher H., Hill R. C., Maurer R., Petcher T. J., Welle H. B., Bakel H. C., Akkerman A. M. Bremazocine: a potent, long-acting opiate kappa-agonist. Life Sci. 1980 Sep 15;27(11):971–978. doi: 10.1016/0024-3205(80)90107-1. [DOI] [PubMed] [Google Scholar]
  21. Schoffelmeer A. N., Rice K. C., Jacobson A. E., Van Gelderen J. G., Hogenboom F., Heijna M. H., Mulder A. H. Mu-, delta- and kappa-opioid receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: studies with fentanyl isothiocyanate. Eur J Pharmacol. 1988 Sep 13;154(2):169–178. doi: 10.1016/0014-2999(88)90094-5. [DOI] [PubMed] [Google Scholar]
  22. Sheehan M. J., Hayes A. G., Tyers M. B. Pharmacology of delta-opioid receptors in the hamster vas deferens. Eur J Pharmacol. 1986 Oct 14;130(1-2):57–64. doi: 10.1016/0014-2999(86)90183-4. [DOI] [PubMed] [Google Scholar]
  23. Stoof J. C., De Boer T., Sminia P., Mulder A. H. Stimulation of D2-dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin. Eur J Pharmacol. 1982 Oct 22;84(3-4):211–214. doi: 10.1016/0014-2999(82)90204-7. [DOI] [PubMed] [Google Scholar]
  24. Takemori A. E., Ikeda M., Portoghese P. S. The mu, kappa and delta properties of various opioid agonists. Eur J Pharmacol. 1986 Apr 29;123(3):357–361. doi: 10.1016/0014-2999(86)90709-0. [DOI] [PubMed] [Google Scholar]
  25. Verlinde C., De Ranter C. Assessment of the kappa-opioid activity of a series of 6,7-benzomorphans in the rabbit vas deferens. Eur J Pharmacol. 1988 Aug 9;153(1):83–87. doi: 10.1016/0014-2999(88)90590-0. [DOI] [PubMed] [Google Scholar]
  26. Vonvoigtlander P. F., Lahti R. A., Ludens J. H. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther. 1983 Jan;224(1):7–12. [PubMed] [Google Scholar]
  27. Werling L. L., Brown S. R., Cox B. M. Opioid receptor regulation of the release of norepinephrine in brain. Neuropharmacology. 1987 Jul;26(7B):987–996. doi: 10.1016/0028-3908(87)90077-3. [DOI] [PubMed] [Google Scholar]
  28. Werling L. L., Frattali A., Portoghese P. S., Takemori A. E., Cox B. M. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. J Pharmacol Exp Ther. 1988 Jul;246(1):282–286. [PubMed] [Google Scholar]
  29. Wood P. L. Multiple opiate receptors: support for unique mu, delta and kappa sites. Neuropharmacology. 1982 Jun;21(6):487–497. doi: 10.1016/0028-3908(82)90038-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES